13-cis retinoic acid treatment of a patient with chemotherapy refractory nephroblastomatosis

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 4, 2009, Pages 296-299

  Witt, Olaf ^a,b   Hämmerling, Susanne ^a   Stockklausner, Clemens ^a   Schenk, Jens Peter ^b   Günther, Patrick ^b   Behnisch, Wolfgang ^a   Hamad, Bajes ^c   Al Mulla, Naima Ali ^c   Kulozik, Andreas ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Nephroblastoma; Nephroblastomatosis; Retinoic acid; Von Willebrand disease; Wilms Tumor

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; ISOTRETINOIN; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DERMATOLOGICAL AGENT;

ADD ON THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CASE REPORT; COMORBIDITY; FEMALE; HUMAN; INFANT; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; PRIORITY JOURNAL; REMISSION; VON WILLEBRAND DISEASE; DRUG RESISTANCE; KIDNEY; KIDNEY TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRECANCER;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DACTINOMYCIN; DERMATOLOGIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFANT; ISOTRETINOIN; KIDNEY; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; PRECANCEROUS CONDITIONS; VINCRISTINE;

EID: 65349157360     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181979c70     Document Type: Article

References (21)

1. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol. 1990;10:1-36.
2. Beckwith JB. Precursor lesions of Wilms tumor: clinical and biological implications. Med Pediatr Oncol. 1993;21:158-168.
3. Perlman EJ, Faria P, Soares A, et al. Hyperplastic perilobar nephroblastomatosis: long-term survival of 52 patients. Pediatr Blood Cancer. 2006;46:203-221.
4. Prasil P, Laberge JM, Bond M, et al. Management decisions in children with nephroblastomatosis. Med Pediatr Oncol. 2000; 35:429-432; discussion 433.
5. Rohrschneider WK, Weirich A, Rieden K, et al. US, CT and MR imaging characteristics of nephroblastomatosis. Pediatr Radiol. 1998;28:435-443.
6. Kumar AP, Pratt CB, Coburn TP, et al. Treatment strategy for nodular renal blastema and nephroblastomatosis associated with Wilms' tumor. J Pediatr Surg. 1978;13:281-285.
7. de Chadarevian JP, Fletcher BD, Chatten J, et al. Massive infantile nephroblastomatosis: a clinical, radiological, and pathological analysis of four cases. Cancer. 1977;39:2294-2305.
8. Haddy TB, Bailie MD, Bernstein J, et al. Bilateral, diffuse nephroblastomatosis: report of a case managed with chemotherapy. J Pediatr. 1977;90:784-786.
9. Coppes MJ, Arnold M, Beckwith JB, et al. Factors affecting the risk of contralateral Wilms tumor development: a report from the National Wilms tumor study group. Cancer. 1999;85: 1616-1625.
10. Laberge JM. Nephroblastomatosis update. Med Pediatr Oncol. 2003;41:96-97.
11. NCT00047138. Chemotherapy before and after surgery in treating children with Wilm's tumor. http://clinicaltrials.gov/ ct2/show/NCT00047138?show-desc= Y#desc.
12. Gilbert T. Vitamin A and kidney development. Nephrol Dial Transplant. 2002;17(suppl 9):78-80.
13. Marlier A, Gilbert T. Expression of retinoic acid-synthesizing and -metabolizing enzymes during nephrogenesis in the rat. Gene Expr Patterns. 2004;5:179-185.
14. Goodyer P, Dehbi M, Torban E, et al. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene. 1995;10:1125-1129.
15. Vincent TS, Re GG, Hazen-Martin DJ, et al. All-trans-retinoic acid-induced growth suppression of blastemal Wilms' tumor. Pediatr Pathol Lab Med. 1996;16:777-789.
16. Zirn B, Samans B, Spangenberg C, et al. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene. 2005; 24:5246-5251.
17. Zirn B, Hartmann O, Samans B, et al. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer. 2006;118:1954-1962.
18. Adamson PC, Reaman G, Finklestein JZ, et al. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997;15:3330-3337.
19. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
20. Michiels J, Schroyens W, Berneman Z, et al. Atypical variant of acquired von Willebrand syndrome in Wilms tumor: is hyaluronic acid secreted by nephroblastoma cells the cause? Clin Appl Thromb Hemost. 2001;7:102-105.
21. Leung RS, Liesner R, Brock P. Coagulopathy as a presenting feature of Wilms tumour. Eur J Pediatr. 2004;163:369-373.